AstraZeneca (NASDAQ:AZN) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

AstraZeneca (NASDAQ:AZN) issued its quarterly earnings data on Tuesday. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03, Zacks reports. AstraZeneca had a net margin of 12.68% and a return on equity of 30.41%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the firm posted $0.87 EPS. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year.

AstraZeneca Stock Performance

AstraZeneca stock traded down $0.25 during mid-day trading on Thursday, reaching $65.04. The company’s stock had a trading volume of 9,762,939 shares, compared to its average volume of 5,263,518. The firm’s fifty day moving average price is $75.79 and its two-hundred day moving average price is $78.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a market capitalization of $201.66 billion, a P/E ratio of 31.12, a PEG ratio of 1.21 and a beta of 0.47.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AZN. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.